简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

IDRA制药公司(纳斯达克代码:IDRA)股价突破200日移动均线0.23美元

2022-12-31 15:22

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA – Get Rating) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.23 and traded as high as $0.36. Idera Pharmaceuticals shares last traded at $0.35, with a volume of 384,137 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Idera Pharmaceuticals in a research note on Friday, December 23rd. They set a "sell" rating on the stock.

Get Idera Pharmaceuticals alerts:

Idera Pharmaceuticals Stock Performance

The firm's 50 day simple moving average is $0.25 and its 200-day simple moving average is $0.23. The company has a market cap of $21.82 million, a price-to-earnings ratio of -1.09 and a beta of 1.36.

Idera Pharmaceuticals (NASDAQ:IDRA – Get Rating) last announced its earnings results on Monday, November 14th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Idera Pharmaceuticals stock. Millennium Management LLC purchased a new stake in shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA – Get Rating) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 122,238 shares of the biotechnology company's stock, valued at approximately $56,000. Millennium Management LLC owned about 0.23% of Idera Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 12.18% of the company's stock.

Idera Pharmaceuticals Company Profile

(Get Rating)

Idera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer.

Read More

  • Get a free copy of the StockNews.com research report on Idera Pharmaceuticals (IDRA)
  • MarketBeat: Week in Review 12/26 – 12/30
  • The Dogs Of Tech: It's Time For A Bite Of These Stocks
  • Does This Acquisition Make Microsoft a Bear Market Buy?
  • Should You Warm up to Generac Stock for the Winter?
  • Is Kintara Therapeutics A Hidden Gem?

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。